Optimi Health taps Adrian Jones for new Australia unit

The Australian subsidiary will manage sales, distribution and prescriber relationships for capsule products supplied to clinics and pharmacies.

Rhea-AI Filing Summary

Optimi Health Corp. (OPTH) announced it established Optimi Australia Pty Ltd as a wholly owned subsidiary for distribution and business development in Australia, and appointed Adrian Jones as Director of Australian Operations. The subsidiary will manage sales, distribution and prescriber relationships, selling 5 mg naturally derived psilocybin capsules and 40 mg and 60 mg MDMA capsules to clinics and pharmacies under Australia's Authorised Prescriber Scheme.

Optimi says the products are manufactured at its Health Canada-licensed GMP facility in Princeton, British Columbia. Jones joins after more than 15 years at Bristol Myers Squibb, most recently leading sales and marketing for its Australian oncology and cardiovascular portfolios.

Key Figures

Naturally derived psilocybin capsule strength: 5 mg MDMA capsule strength: 40 mg MDMA capsule strength: 60 mg +1 more

4 metrics

Naturally derived psilocybin capsule strength 5 mg Product to be sold in Australia

MDMA capsule strength 40 mg Product to be sold in Australia

MDMA capsule strength 60 mg Product to be sold in Australia

Experience at Bristol Myers Squibb More than 15 years Adrian Jones's experience before joining Optimi

Key Terms

Authorised Prescriber Scheme, GMP-compliant, Special Access Program, active pharmaceutical ingredients

4 terms

Authorised Prescriber Scheme regulatory

"under Australia's Authorised Prescriber Scheme"

A government-authorised prescriber scheme lets designated healthcare professionals routinely prescribe a specific medicine or class of medicines for a group of patients without needing case-by-case approvals, similar to giving a trusted chef a standing recipe rather than checking each meal. For investors, it matters because such a scheme can speed patient access, increase predictable demand, and reduce regulatory hurdles for manufacturers, affecting sales and revenue forecasts.

GMP-compliant technical

"at its GMP-compliant facility in British Columbia"

Good Manufacturing Practice (GMP) compliant means a maker follows established, inspectable rules for producing medicines, medical devices, or other regulated products so each batch is safe, consistent and of expected quality. For investors, GMP compliance lowers the chance of regulatory shutdowns, recalls or delays and increases the likelihood products can be sold; think of it as a verified recipe and checklist that keeps a factory from making faulty batches.

Special Access Program regulatory

"accessible in Canada through the Special Access Program"

A special access program is a regulated pathway that lets patients use an experimental drug, vaccine, or medical device outside clinical trials when no approved options are available. Think of it like allowing a small number of people to try a prototype product before wide release; for investors it can create early, limited revenue, generate real‑world safety and use data, and carry regulatory and reputational risks that can affect a company’s valuation.

active pharmaceutical ingredients technical

"supplies both active pharmaceutical ingredients and finished dosage forms"

The active pharmaceutical ingredient (API) is the specific chemical or biological substance in a medicine that produces the intended health effect — the ‘engine’ that treats, prevents or diagnoses a condition. Investors watch APIs because they determine a drug’s cost, quality, regulatory approval and patent protection; shortages, manufacturing problems or competition at the API level can directly affect a drug maker’s sales and valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What products will OPTH distribute in Australia?

Optimi Australia will sell 5 mg naturally derived psilocybin capsules and 40 mg and 60 mg MDMA capsules to clinics and pharmacies under Australia's Authorised Prescriber Scheme. Optimi says all products are manufactured at its Health Canada-licensed GMP facility in Princeton, British Columbia.

Who is leading OPTH's Australian operations?

Adrian Jones was appointed Director of Australian Operations for Optimi Australia. He joins after more than 15 years at Bristol Myers Squibb, most recently as Associate Director, Head of Sales and Marketing for its Australian oncology and cardiovascular portfolios. His earlier career included psychiatry roles with Eli Lilly and Hospira.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:00 AM EDT Accepted by SEC EDGAR 10/26/2026 - 08:00 AM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-43304

Optimi Health Corp.
(Translation of registrant's name into English)

269 David Brown Way
Princeton, B.C. V0X 1W0
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Optimi Health Corp.
		(Registrant)
Date: October 26, 2026		/s/ Dane Stevens
		Dane Stevens
		Chief Executive Officer, Chief Marketing Officer and Director

EXHIBIT 99.1

 

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical developer and manufacturer of regulated psychedelic drug products, today announced the establishment of Optimi Australia Pty Ltd ("Optimi Australia"), a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations.

Optimi Australia will handle the Company's sales, distribution, and prescriber relationships across the country. It will sell Optimi's finished drug products, 5mg naturally derived psilocybin capsules and 40mg and 60mg MDMA capsules, to clinics and pharmacies under Australia's Authorised Prescriber Scheme. All products are manufactured at the Company's Health Canada-licensed GMP facility in Princeton, British Columbia.

Mr. Jones joins Optimi after more than 15 years at Bristol Myers Squibb, most recently as Associate Director, Head of Sales and Marketing for its Australian oncology and cardiovascular portfolios, where he led national commercial teams and served as launch lead for first-in-class therapies including Opdivo and Camzyos. His early career includes psychiatry roles with Eli Lilly and Hospira.

"Australia is our first commercial market and we believe demand from authorized prescribers there continues to grow," said Dane Stevens, Chief Executive Officer of Optimi. "Optimi Australia puts our team on the ground, and in Adrian we have a leader with extensive experience launching new therapies in this market."

"My immediate focus is to understand the needs of the clinician and to help them deliver therapy as efficiently and effectively as possible," said Adrian Jones, Director of Australian Operations.

Authorised prescribers, clinics, and pharmacies seeking product information or account setup can contact Adrian Jones at adrian@optimihealth.ca or visit the Company's Australian website, www.optimi.com.au.

About Optimi Health Corp.

Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) is a commercial-stage pharmaceutical company focused on developing, manufacturing, and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facility in British Columbia, Canada.

Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorised Prescriber Scheme and accessible in Canada through the Special Access Program. The Company plans to advance a Health Canada-approved Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder and a proposed Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder.

Learn more at www.optimi.net.

Company Contact:

Dane Stevens, Chief Executive Officer
Telephone: (778) 761-4551
investors@optimi.net

Australian Inquiries:

Adrian Jones
Director of Australian Operations
Optimi Australia Pty Ltd
E. adrian@optimihealth.ca
M. +61 (0) 408 117 700
W. www.optimi.com.au

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). All statements other than statements of historical fact contained in this news release, including statements regarding the anticipated role, responsibilities, and operations of Optimi Australia Pty Ltd, the expansion of the Company's clinic and pharmacy network in Australia, anticipated demand for the Company’s products in Australia, the expected contributions of Mr. Jones, the results of the Company’s clinical trials, the Company's growth objectives, and the Company's business plans and commercial strategy, are forward-looking statements. Forward-looking statements are necessarily based upon a number of material assumptions, including that the Authorised Prescriber Scheme will remain in place on substantially current terms, that authorised prescribers will continue to prescribe the Company's products, and that the Company will have sufficient capital to fund its Australian operations. While considered reasonable by management, these assumptions are inherently subject to significant business, economic, regulatory and competitive uncertainties and contingencies. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such statements, including risks related to changes in the Australian regulatory framework for psilocybin and MDMA, the number of authorised prescribers, controlled substance import, export, and permitting requirements, the Company's ability to maintain its licences, the commercialization of the Company's products, the results and timing of clinical trials, foreign operations, the Company's ability to obtain financing, and general market conditions, as well as the risks described under "Risk Factors" in the Company's most recent filings available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.3 KB